Trial Site Detail

 

Drug:
QINLOCK Ripretinib DCC-2618
Trial:
Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)
Conditions: Gastrointestinal Stromal Tumor
Trial Status:
Active, not recruiting

 

Dana Farber Cancer Institute

450 Brookline Ave     
Boston , MA 02215-5450
USA

 

Principal Investigator:
George Demetri, MD
Contact:
Tarsha Huftalen, RN, BSN 617-632-5117 tmhuftalen@partners.org
Activation Status of this Site:
Closed
Notes about this Site:
Dana Farber Cancer Institute Website:
http://www.dana-farber.org/Research/Clinical-Trials.aspx

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.